Cut through the noise.
Trade on the signal.

A weekly synthesis of institutional-grade financial reports and market mechanics.

No spam. Unsubscribe anytime.

All ReportsWhite Diamond Research×/ Market Intelligence

White Diamond Research

12 of 12 reports
UMAC$24.98
+2.17%
UMACUnusual Machines

"Infinite Demand" and a $30 Price Target: Why White Diamond Is Bullish on Unusual Machines After a 25% Post-Offering Selloff

White Diamond interviewed CEO Dr. Allan Evans after UMAC fell 25% post-offering and came away bullish — Evans says the company is supply-constrained, 80-90% military-exposed, and experiencing demand he calls "infinite...

ZJK$1.91
-19.24%
ZJKZJK Industrial

ZJK Industrial Is A Boring Nuts And Bolts Manufacturer – Evidence Suggests Their Claimed Collaboration With Nvidia Is A Lie

ZJK Industrial stock fraud investigation reveals fabricated Nvidia partnership, potential AI hype manipulation, and suspicious related-party transactions threatening investor confidence in Chinese fastener manufacture...

TELO$1.42
+13.60%
TELOTelo Therapeutics

Telomir Pharmaceuticals Is A Biotech Pump And Dump Scheme Remaining In the Preclinical Stage

Telomir Pharmaceuticals (TELO) exposed: Biotech pump and dump scheme with missing preclinical data, questionable founder history, extreme overvaluation, and potential stock collapse under $1 in 2025

ILLR$0.16
+4.59%
ILLRTriller Group

The Agba Group/Triller Merger Is A Scheme to Temporarily Boost Agba’s Stock Price – Both Companies Are Practically Worthless/Bankrupt And It Likely Won’t Get Approved By Regulators Anyways

White Diamond Research exposes AGBA-Triller merger as a stock manipulation scheme, revealing financial fraud, regulatory risks, and zero business synergy in a damning analysis of two practically bankrupt companies see...

AUID$1.10
-2.65%
AUID

Former Top Executive at authID Spills the Beans about its Selfie Identification Product: “There is No Market Fit”

authID stock exposed: Former executive reveals zero market fit for selfie authentication tech, alleging misleading investor communications, potential SEC violations, and unsustainable $50M market valuation with minima...

MPU$0.32
-6.45%
MPU

Mega Matrix Corp’s Recent Acquisition, FlexTV, Appears To Already Be Its 5th Consecutive Business Failure – 50c Price Target

White Diamond Research exposes Mega Matrix's FlexTV acquisition as 5th business failure, revealing overvaluation, fake reviews, and 80% potential stock decline with 50¢ price target for MPU

PLSE$25.60
+0.59%
PLSEPulse Biosciences

Evidence Reveals Pulse Biosciences Is A Joke – It’s Years Late To The Pulsed Field Ablation Market And Its “Nanosecond” Technology Is Impractical And Not Novel – $1 Price Target

Pulse Biosciences (PLSE) faces critical challenges in cardiac ablation technology, burning $15M quarterly with minimal revenue, unproven nsPFA technology, and significant bankruptcy risks in competitive medical device...

RPMT$0.75
-0.53%
RPMT

Rego Payment Architectures has A Weak Product, Recently Added Debt And Significant Dilution – 25c 1-Year Price Target

White Diamond Research exposes Rego Payment Architectures (RPMT) with a 75% downside risk, highlighting Mazoola's failed product, mounting $20M debt, minimal revenue, and potential stock dilution in the competitive fi...

USBC$0.42
+13.24%
USBC

Know Labs Is An Obvious Medical Device Scam, We’re Calling: “Theranos’ Retarded Cousin”

White Diamond Research exposes Know Labs (KNW) as a potential medical device scam, revealing zero revenue, unproven glucose monitoring technology, massive share dilution, and lack of scientific validation in devastati...

VERU$2.95
-1.34%
sabizabulinVERU

Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

White Diamond Research exposes critical flaws in Veru's COVID-19 drug trial, revealing data integrity issues, methodological problems, and potential FDA rejection risks for sabizabulin treatment

VERU$2.95
-1.34%
VERUVERU

Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment

AZ$5.72
+1.24%
AZ

A2Z Smart Technologies: Used To Be Called Inrob Tech (A Pump And Dump Scam), Management Has A Shady Past, and Related Party Transactions – 50c Price Target

Exposing A2Z Smart Technologies (AZ) stock fraud: White Diamond Research reveals pump-and-dump scheme, questionable leadership, minimal revenue, and projected 85% stock price decline to $0.50 per share